Bart Biesmans

5.3k total citations · 2 hit papers
20 papers, 2.5k citations indexed

About

Bart Biesmans is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Bart Biesmans has authored 20 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Bart Biesmans's work include Colorectal Cancer Treatments and Studies (19 papers), Genetic factors in colorectal cancer (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Bart Biesmans is often cited by papers focused on Colorectal Cancer Treatments and Studies (19 papers), Genetic factors in colorectal cancer (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Bart Biesmans collaborates with scholars based in Belgium, Switzerland and France. Bart Biesmans's co-authors include Sabine Tejpar, Eric Van Cutsem, Wendy De Roock, Gert De Hertogh, Marc Peeters, Yves Humblet, Hubert Piessevaux, Nicola Personeni, Joris De Schutter and Jef De Schutter and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Bart Biesmans

20 papers receiving 2.4k citations

Hit Papers

Prognostic Role of KRAS and BRAF in Stage II and III Rese... 2007 2026 2013 2019 2009 2007 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
    2009 893 citations Arnaud Roth, Sabine Tejpar et al. Journal of Clinical Oncology profile →
  2. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
    2007 660 citations Wendy De Roock, Hubert Piessevaux et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bart Biesmans Belgium 11 2.1k 1.1k 861 478 471 20 2.5k
Wendy De Roock Belgium 16 2.3k 1.1× 963 0.9× 1.1k 1.3× 560 1.2× 657 1.4× 31 2.8k
Cristiana Lupi Italy 18 1.7k 0.8× 608 0.5× 631 0.7× 370 0.8× 708 1.5× 35 2.8k
David J. Mauro United States 11 1.6k 0.7× 451 0.4× 755 0.9× 376 0.8× 459 1.0× 26 2.0k
Elisa Sensi Italy 20 1.5k 0.7× 555 0.5× 586 0.7× 396 0.8× 609 1.3× 44 2.3k
Van K. Morris United States 28 2.3k 1.1× 1.1k 1.0× 840 1.0× 913 1.9× 773 1.6× 162 3.1k
M. Elisa Vink-Börger Netherlands 9 1.3k 0.6× 487 0.4× 535 0.6× 340 0.7× 291 0.6× 9 1.6k
Ilona Kocáková Czechia 10 1.6k 0.7× 404 0.4× 695 0.8× 336 0.7× 282 0.6× 33 1.9k
Wataru Okamoto Japan 23 1.2k 0.5× 402 0.4× 777 0.9× 375 0.8× 555 1.2× 97 1.8k
Yasutoshi Kuboki Japan 27 2.1k 1.0× 449 0.4× 1.2k 1.4× 309 0.6× 556 1.2× 143 2.8k
Shao-Chun Chang United States 7 1.2k 0.5× 341 0.3× 448 0.5× 349 0.7× 637 1.4× 7 2.2k

Countries citing papers authored by Bart Biesmans

Since Specialization
Citations

This map shows the geographic impact of Bart Biesmans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Biesmans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Biesmans more than expected).

Fields of papers citing papers by Bart Biesmans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Biesmans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Biesmans. The network helps show where Bart Biesmans may publish in the future.

Co-authorship network of co-authors of Bart Biesmans

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Biesmans. A scholar is included among the top collaborators of Bart Biesmans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Biesmans. Bart Biesmans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Declercq, Jeroen, Bart Jacobs, Bart Biesmans, et al.. (2015). Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter ofFURINIs Not Prognostic to Colon Cancer. BioMed Research International. 2015. 1–8. 3 indexed citations
2.
Vriendt, Veerle de, Wendy De Roock, Antonio Fabio Di Narzo, et al.. (2013). DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. Biomarkers. 18(6). 516–524. 19 indexed citations
3.
Dijkstra, Jeroen R., Frank J.M. Opdam, Jerry Boonyaratanakornkit, et al.. (2012). Implementation of Formalin-Fixed, Paraffin-Embedded Cell Line Pellets as High-Quality Process Controls in Quality Assessment Programs for KRAS Mutation Analysis. Journal of Molecular Diagnostics. 14(3). 187–191. 10 indexed citations
4.
Dijkstra, Jeroen R., D.A.M. Heideman, Gerrit A. Meijer, et al.. (2012). KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 462(1). 39–46. 22 indexed citations
5.
Vriendt, Veerle de, Wendy De Roock, Antonio Fabio Di Narzo, et al.. (2012). P1.28 Dusp4 Expression as A Marker of Heterogeneous Signaling in Colorectal Cancer Patients. Annals of Oncology. 23. v20–v20. 9 indexed citations
6.
Prenen, Hans, Jef De Schutter, Bart Jacobs, et al.. (2009). PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer. Clinical Cancer Research. 15(9). 3184–3188. 241 indexed citations
7.
Kotoula, Vassiliki, Elpida Charalambous, Bart Biesmans, et al.. (2009). Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics. PLoS ONE. 4(11). e7746–e7746. 69 indexed citations
8.
Roock, Wendy De, Jef De Schutter, Hans Prenen, et al.. (2009). PIK3CA mutations do not confer resistance to the EGFR-inhibitor cetuximab in chemorefractory metastatic colorectal cancer. 1 indexed citations
9.
Prenen, Hans, Bart Jacobs, Wendy De Roock, et al.. (2009). Use of amphiregulin and epiregulin mRNA expression in primary tumors to predict outcome in metastatic colorectal cancer treated with cetuximab. Journal of Clinical Oncology. 27(15_suppl). 4019–4019. 10 indexed citations
10.
Roock, Wendy De, Bart Biesmans, Jef De Schutter, & Sabine Tejpar. (2009). Clinical Biomarkers in Oncology. Molecular Diagnosis & Therapy. 13(2). 103–114. 33 indexed citations
11.
Roock, Wendy De, M. Janssens, Bart Biesmans, et al.. (2009). DUSPs as markers of MEK/Erk activation in primary colorectal cancer. Journal of Clinical Oncology. 27(15_suppl). 4064–4064. 5 indexed citations
12.
Lambrechts, Diether, Wendy De Roock, Hans Prenen, et al.. (2009). The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. Journal of Clinical Oncology. 27(15_suppl). 4020–4020. 36 indexed citations
13.
Roth, Arnaud, Sabine Tejpar, Mauro Delorenzi, et al.. (2009). Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. Journal of Clinical Oncology. 28(3). 466–474. 893 indexed citations breakdown →
14.
Jacobs, Bart, Wendy De Roock, Hubert Piessevaux, et al.. (2009). Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab. Journal of Clinical Oncology. 27(30). 5068–5074. 276 indexed citations
15.
Personeni, Nicola, Steffen Fieuws, Hubert Piessevaux, et al.. (2008). Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study. Clinical Cancer Research. 14(18). 5869–5876. 129 indexed citations
16.
Tejpar, Sabine, Wendy De Roock, Bart Biesmans, et al.. (2008). Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease.. Ghent University Academic Bibliography (Ghent University). 9 indexed citations
17.
Roock, Wendy De, M. Janssens, Bart Biesmans, et al.. (2008). 98 POSTER DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease. European Journal of Cancer Supplements. 6(12). 33–33. 3 indexed citations
18.
Personeni, Nicola, Hubert Piessevaux, Steffen Fieuws, et al.. (2008). Association between EGFR gene copy number and KRAS status and impact on outcome prediction in colorectal cancer patients treated with cetuximab. Journal of Clinical Oncology. 26(15_suppl). 11093–11093. 5 indexed citations
19.
Roock, Wendy De, Hubert Piessevaux, Joris De Schutter, et al.. (2007). KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Annals of Oncology. 19(3). 508–515. 660 indexed citations breakdown →
20.
Roock, Wendy De, Joris De Schutter, M. Janssens, et al.. (2007). KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab. Journal of Clinical Oncology. 25(18_suppl). 4132–4132. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wendy De Roock Breakdown of academic impact, for papers by Cristiana Lupi Breakdown of academic impact, for papers by David J. Mauro Breakdown of academic impact, for papers by Elisa Sensi Breakdown of academic impact, for papers by Van K. Morris Breakdown of academic impact, for papers by M. Elisa Vink-Börger Breakdown of academic impact, for papers by Ilona Kocáková Breakdown of academic impact, for papers by Wataru Okamoto Breakdown of academic impact, for papers by Yasutoshi Kuboki Breakdown of academic impact, for papers by Shao-Chun Chang
Rankless by CCL
2026